CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Effects of treatment with liraglutide 3.0 mg in subjects with BMI < 35 and BMI ≥35 kg/m2: subgroup analysis of the SCALE Obesity and Prediabetes 56-week trial
DOI 10.1055/s-0036-1580948
Bibliografische Angaben
Nachweis in CareLit
Autor:innenJ Aberle, T Wehrhahn, L Van Gaal, C Le Roux, X Pi-Sunyer, J Wilding, F Greenway, S Lilleøre, B Claudius
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
This post-hoc analysis investigated effects of liraglutide 3.0 mg in those with BMI < 35 v ≥35 kg/m2 at baseline in the SCALE Obesity and Prediabetes trial.3731 adults (mean ± SD: age 45.1 ± 12.0y; BMI 38.3 ± 6.4 kg/m2; male 21.5%; with prediabetes 61.2%) were randomized 2:1 to liraglutide 3.0 mg or placebo as adjunct to diet and exercise (D&E) for 56 weeks (W). Treatment effect across baseline BMI subgroups was eva…
Zitieren
Zitierempfehlung
J Aberle, T Wehrhahn, L Van Gaal, C Le Roux, X Pi-Sunyer, J Wilding, F Greenway, S Lilleøre, B Claudius (2016) Effects of treatment with liraglutide 3.0 mg in subjects with BMI < 35 and BMI ≥35 kg/m2: subgroup analysis of the SCALE Obesity and Prediabetes 56-week trial. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0036-1580948
Mit CareLit weiterarbeiten